CurveBeam AI (ASX:CVB) Jumps 20% as China Greenlights A$4M Equity Injection

CurveBeam AI Gets the Green Light

CurveBeam AI (ASX:CVB) shares surged 20% today after the company received formal China ODI approval for its previously announced strategic investment supporting long term expansion into China. Importantly, this is not a new transaction. Rather, it represents a key regulatory greenlight that allows Chinese capital to legally move offshore and be invested into CurveBeam’s operations.

The approved investment is a A$4 million equity injection, expected to be completed this month at a share price of 40.5c. This represents a meaningful premium to the company’s prior trading price and provides a strong external validation of CurveBeam’s strategy and technology. This funding is intended to support the company’s commercial expansion within the Chinese market.

This marks the first tranche of a broader funding arrangement of up to A$10 million. A further A$6 million is expected to be invested into CurveBeam as specific operational and commercial milestones are achieved. From an investor perspective, the key takeaway is that this approval removes a major regulatory hurdle, strengthens the balance sheet, and materially de risks the company’s China growth strategy while aligning it with long term capital support.

What are the Best ASX Stocks to invest in right now?

Check our buy/sell tips

China Expansion News

We view this as a strong and meaningful signal for CurveBeam. Against the backdrop of heightened regulatory scrutiny and capital controls in China, securing approval for offshore investment is not straightforward. The fact that this funding has now been cleared highlights both the strategic importance of the partnership and the perceived value of CurveBeam’s imaging technology within the Chinese healthcare system.

Importantly, this investment sits within a 10 year exclusive commercialisation agreement covering Greater China, providing long term market access rather than a short term distribution arrangement. The partnership is backed by WEGO Orthopaedics, a leading domestic healthcare group with significant scale and influence.

CurveBeam AI Clears Final Regulatory Hurdle

For investors who may not be familiar with the earlier announcement, CurveBeam outlined the framework of this partnership back in October. At that time, the company disclosed a long duration agreement covering sales, marketing, distribution, manufacturing, regulatory approvals, and IP protection across China. The key risks highlighted then were regulatory approval and capital transfer risk. With China ODI approval now in hand, those risks have effectively been removed. The China strategy has shifted from being signed but conditional to fully executable.

As we have discussed in previous articles, CurveBeam’s revenue model is built on two core pillars. The first is hardware sales, specifically weight bearing CT scanners sold into hospitals and orthopaedic centres. The second is AI enabled SaaS, where clinical assessment tools and software are layered on top of the hardware, generating recurring revenue per installed scanner over time.

Under this specific agreement, WEGO has the right to manufacture the technology in China, which is a critical enabler of scale in that market. Importantly, the agreement explicitly references long term revenue participation and royalties, while indicating that CurveBeam retains ownership of its core IP. In our view, this structure has the potential to translate into highly attractive, high margin profitability over the long term as volumes scale and software penetration increases.

CVB investor takeaway

The investor takeaway here is that there are clear parallels between CurveBeam and 4DMedical at a business model level, which helps frame expectations around commercial momentum. Both companies operate at the intersection of medical imaging hardware and high margin software, and both benefit from strong operating leverage once installations scale and utilisation increases.

That said, there are important differences. CurveBeam’s model requires hospitals and clinics to adopt new hardware systems, which typically results in longer sales cycles and higher upfront friction compared with 4DMedical’s software led approach that integrates onto existing imaging infrastructure. This distinction matters from a timing perspective. Hardware led deployments tend to move more slowly, but they also create stickier customer relationships once embedded. Over time, both models can deliver attractive incremental margins as software penetration and scan volumes expand.

From a commercial standpoint, regulatory approval and capital certainty now allow CurveBeam’s China strategy to move into execution mode, which supports the case for continued momentum into 2026. However, from a market perspective, it is also important to remain disciplined. The stock has moved sharply higher and technical indicators suggest near term conditions are extended. For investors considering entry, waiting for a pullback toward the 7.5c level may provide a more balanced risk reward profile, particularly for those looking to build positions with a medium to long term horizon rather than chasing short term momentum.